Small Cap REIT Pays...
Health Care: Drugs
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$15.20 -0.20 | -1.30%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 15.20 |
| 52 Week High | 16.48 |
| 52 Week Low | 4.46 |
| Avg. Daily Vol. (Mil) | 1.43 |
| Beta (3 year) | 2.94 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,229.23 |
| Shares Out (Mil) | 80.87 |
| Float (Mil) | 80.65 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 10.00 |
| Current Ratio | 10.10 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.05 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 109.92 |
| Price/Book | 6.31 |
| Price/Cash Flow | -16.40 |
| Per Share Data | |
| Earnings | -0.98 |
| Sales | 0.14 |
| Book Value | 2.41 |
| Cash Flow | -0.93 |
| Business Summary | |
|---|---|
| Celldex Therapeutics, Inc., is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. | |
| General Information | |
| 119 Fourth Avenue
Needham, MA 02494 |
|
| www.celldextherapeutics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 106 | |
| CEO: Anthony S. Marucci | |
| Short Interest | |
| Current Month (Mil) | 7.71 |
| Previous Month (Mil) | 7.46 |
| Short Interest Ratio (Days) | 7.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -34.10 |
| Return on Investments | -38.00 |
| Profitability | |
| Gross Margin | 7.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CLDX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- Userbio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
Latest CLDX Headlines from TheStreet
- 'Mad Money' Lightning Round: Don't Sell MasterCard 06.20.13 | 06:06 am
- Cramer's 'Mad Money' Recap: Time to Change Your Strategy 06.19.13 | 08:06 pm
- 4 Stocks Spiking on Unusual Volume 06.10.13 | 02:06 pm
- 4 Stocks Spiking on Big Volume 06.03.13 | 02:06 pm
- Cramer's Top Stock Picks: CLDX OXY TEAR TSLA 06.01.13 | 06:06 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 05.31.13 | 08:05 pm
- Celldex Therapeutics To Present At Two Upcoming Investor Conferences 05.22.13 | 10:05 am
- Celldex Therapeutics Announces Upcoming Presentation At The Credit Suisse 2013 Antibody Day 05.06.13 | 10:05 am
- Celldex Reports First Quarter 2013 Financial Results 05.02.13 | 08:05 am
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
Press Releases for CLDX
- Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells In Phase 1 Study; Future Development Planned - Business Wire 12.11.12 | 08:12 am
- Final Data From Celldex Therapeutic’s CDX-011 Phase 2 Study In Metastatic Breast Cancer Supports Overall Survival Benefit In Patients With High GPNMB Expression - Business Wire 12.08.12 | 08:12 am
- Celldex Therapeutics Announces Upcoming Presentation At Oppenheimer Healthcare Conference - Business Wire 12.07.12 | 11:12 am
- Celldex Therapeutics Announces Upcoming Data Presentations On CDX-1127 And CDX-011 - Business Wire 12.04.12 | 10:12 am
- Celldex Therapeutics Announces Upcoming Presentation At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.30.12 | 08:11 am
- Celldex Therapeutics Announces Positive Three-Year Survival Data For Rindopepimut Phase 2 Clinical Program - Business Wire 11.15.12 | 05:11 pm
- Celldex Therapeutics Announces Upcoming Presentation At Lazard Capital Markets Healthcare Conference - Business Wire 11.09.12 | 09:11 am
- Celldex Announces Upcoming Data Presentation At The American Society Of Hematology 54th Annual Meeting And Exposition - Business Wire 11.05.12 | 04:11 pm
- Celldex Announces Upcoming Data Presentations At The Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day - Business Wire 11.05.12 | 07:11 am
- Celldex Reports Third Quarter 2012 Financial Results - Business Wire 11.01.12 | 08:11 am
Partner Headlines for CLDX
- Pre-Market Earnings Report for March 7, 2013 : CNQ, KR, BTE, SFD, NAV, JW/A, FGP, CIEN, EPL, PRIM, CMN, CLDX - NASDAQ 03.06.13 | 09:03 pm
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Pre-Market Most Active for Dec 11, 2012 : AIG, BAC, HTZ, NOK, FB, HCA, GSK, SIRI, AAPL, URBN, QQQ, CLDX - NASDAQ 12.11.12 | 01:12 pm
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics - Benzinga 11.02.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Pre-Market Earnings Report for August 10, 2012 : BAM, JCP, HAR, CYD, HSFT, CLDX, HZNP, SCR, XIN, URRE, HSKA, DLGC - NASDAQ 08.09.12 | 08:08 pm
- Even In Clinical Studies, Big Potential For MRI-Guided Procedures - Seeking Alpha 06.28.12 | 09:06 am
- IsoRay: A Potential Small-Cap Bio-Pharma Multi-Bagger - Seeking Alpha 05.29.12 | 09:05 am
- Pre-Market Most Active for May 24, 2012 : BAC, PPL, EMC, NTAP, HPQ, MTGE, CLDX, TS, FB, MT, QQQ, VOD - NASDAQ 05.24.12 | 12:05 pm
